Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Systemic inflammation mediator" is not the name of a specific molecule, receptor, or protein. Instead, it is a broad descriptive term referring to any substance that mediates or promotes systemic inflammation in the body. These mediators include diverse classes such as cytokines (e.g., interleukin 1 [IL‑1], tumor necrosis factor alpha [TNF‑α]), chemokines, prostaglandins, leukotrienes, histamine, bradykinin, and complement proteins[1][3][5]. They are released by immune cells in response to infection or injury and orchestrate various aspects of the inflammatory process—such as increasing blood flow to affected tissues, recruiting immune cells to sites of damage or infection, inducing fever via effects on the hypothalamus (as with IL‑1 and prostaglandin E2), promoting pain sensation by sensitizing nerve endings (as with prostaglandins), and regulating vascular permeability[6][7]. The term "systemic" refers to their action throughout the body rather than at a localized site. Excessive release of these mediators can lead to harmful conditions such as sepsis or chronic inflammatory diseases. Because "systemic inflammation mediator" does not refer to one defined molecular entity but rather an entire class of substances involved in systemic inflammatory responses—and because there are no drugs that target this generic category directly—it is not considered an appropriate therapeutic target name. For structured data purposes you should instead specify individual molecules such as "Interleukin 1", "Tumor necrosis factor alpha", etc.[1][3][5] > “Inflammatory mediators are substances released by cells in the immune system that help modulate inflammation… Examples include cytokines, prostaglandins and histamine.”[1] > “Systemic inflammation… is a cascade of chemical reactions… White blood cells patrol different areas looking for infection… IL‑1 causes fever; TNF-alpha contributes to cachexia.”[7] In summary: “Systemic inflammation mediator” is not a canonical target but rather an umbrella term for many different molecules involved in systemic inflammatory processes. It should be replaced with specific names for structured scientific use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Systemic inflammation mediator.